Synthetic Genomics Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Synthetic Genomics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013283
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Synthetic Genomics Inc (Synthetic Genomics) is a provider of synthetic biology and synthetic genomics solutions. The company offers DNA synthesis services, instrumentation, reagents, and bioinformatics services and software packages. It offers solutions in genomics research, bioproduction, and applied products. Synthetic Genomics caters to academic and commercial research and development organizations. It also provides production of nutritionals, pharmaceuticals, vaccines, and bio-industrial products derived from renewable biological resources. The company operates in partnership with other medical organizations to offer its products. Synthetic Genomics is headquartered in La Jolla, California, the US..

Synthetic Genomics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Synthetic Genomics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Synthetic Genomics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Synthetic Genomics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Synthetic Genomics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Synthetic Genomics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Synthetic Genomics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Synthetic Genomics Acquires DNA Technology Patent Portfolio From febit 11
Venture Financing 12
Synthetic Genomics Raises US$10 Million In Venture Financing 12
Partnerships 13
Janssen Vaccines & Prevention Enters into Research and Licensing Option Agreement with Synthetic Genomics 13
Synthetic Genomics Expands R&D Agreement with Lung Biotech 14
SGI-DNA Enters Into Agreement With Integrated DNA Technologies For Synthetic DNA Products 15
Licensing Agreements 16
Synthetic Genomics Enters into Licensing Agreement with Arcturus Therapeutics 16
Synthetic Genomics Enters Licensing Agreement with Gen9 for Synthetic Biology Technology Patents 17
New England Biolabs Enters Into Licensing Agreement With Synthetic Genomics 18
Equity Offering 19
Synthetic Genomics Raises USD50 Million in Private Placement of Shares 19
Synthetic Genomics Raises USD50 Million in Private Placement of Shares 20
Acquisition 21
Monsanto Invests In Synthetic Genomics, Developer Of Genomic-Driven Solutions 21
Synthetic Genomics Secures An Additional US$35 Million Investment From Life Technologies 22
Synthetic Genomics Inc – Key Competitors 23
Synthetic Genomics Inc – Key Employees 24
Synthetic Genomics Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Corporate Communications 26
Nov 09, 2016: Synthetic Genomics Appoints Tina Nova, Ph.D., and William McKee to Board of Directors 26
Government and Public Interest 27
Mar 24, 2016: First Minimal Synthetic Bacterial Cell Designed and Constructed by Scientists at Venter Institute and Synthetic Genomics 27
Product News 29
Aug 29, 2016: Synthetic Genomics team engineers Vmax, an advantaged next-generation host organism for a wide range of biotechnology applications 29
Aug 22, 2017: BioXp Genomic Workstation Makes European Debut at VIB Research Institute in Belgium 30
Jun 01, 2017: Synthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis’ Clinical Trials 31
Jan 09, 2017: Synthetic Genomics Launches Vmax Express, a Next-Generation Protein Expression Platform for the Biotech Industry 32
Other Significant Developments 33
Jul 20, 2016: SGI-DNA, A Synthetic Genomics Company, Announces Exclusive Global Distribution Agreement for Reagents with VWR 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Synthetic Genomics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Synthetic Genomics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Synthetic Genomics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Synthetic Genomics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Synthetic Genomics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Synthetic Genomics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Synthetic Genomics Acquires DNA Technology Patent Portfolio From febit 11
Synthetic Genomics Raises US$10 Million In Venture Financing 12
Janssen Vaccines & Prevention Enters into Research and Licensing Option Agreement with Synthetic Genomics 13
Synthetic Genomics Expands R&D Agreement with Lung Biotech 14
SGI-DNA Enters Into Agreement With Integrated DNA Technologies For Synthetic DNA Products 15
Synthetic Genomics Enters into Licensing Agreement with Arcturus Therapeutics 16
Synthetic Genomics Enters Licensing Agreement with Gen9 for Synthetic Biology Technology Patents 17
New England Biolabs Enters Into Licensing Agreement With Synthetic Genomics 18
Synthetic Genomics Raises USD50 Million in Private Placement of Shares 19
Synthetic Genomics Raises USD50 Million in Private Placement of Shares 20
Monsanto Invests In Synthetic Genomics, Developer Of Genomic-Driven Solutions 21
Synthetic Genomics Secures An Additional US$35 Million Investment From Life Technologies 22
Synthetic Genomics Inc, Key Competitors 23
Synthetic Genomics Inc, Key Employees 24
Synthetic Genomics Inc, Subsidiaries 25

★海外企業調査レポート[Synthetic Genomics Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fastenal Co:企業の戦略・SWOT・財務分析
    Fastenal Co - Strategy, SWOT and Corporate Finance Report Summary Fastenal Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • PT PLN (Persero):発電所・企業SWOT分析
    PT PLN (Persero) – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (e …
  • Grupo Aeromexico SAB de CV:企業の財務・戦略的SWOT分析
    Grupo Aeromexico SAB de CV - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Zygo Corporation:企業の戦略的SWOT分析
    Zygo Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Global Bioenergies SA (ALGBE):企業の財務・戦略的SWOT分析
    Global Bioenergies SA (ALGBE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Cerus Corp (CERS):医療機器:M&Aディール及び事業提携情報
    Summary Cerus Corp (Cerus) is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes the INTERCEPT Blood System to enhance blood safety. INTERCEPT Blood System reduces the risk of transfusion-transmitted infections by inactivating a wide r …
  • Pulse Seismic Inc (PSD):企業の財務・戦略的SWOT分析
    Summary Pulse Seismic Inc (Pulse), formerly Pulse Data Inc is a provider of seismic data library for oil and gas exploration. The company acquires, markets and licenses 2D and 3D seismic data to the western Canadian energy sector. It offers services such as project cost tracking, scouting, geophysic …
  • Power Engineering Consulting 2 Joint Stock Company (TV2):企業の財務・戦略的SWOT分析
    Summary Power Engineering Consulting Joint Stock Company 2 (PECC2), a subsidiary of Vietnam Electricity is a power company that designs, investigates, supervises and constructs electric power projects and other industrial and civil utilities. The company provides consultancy services comprise prepar …
  • Horizon Discovery Group Plc:企業のM&A・事業提携・投資動向
    Horizon Discovery Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Horizon Discovery Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Centrose LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Centrose LLC (Centrose) is a precision drug company that develops medicines to target diseased tissues. The company's product pipeline includes EDC1 (Dysadherin), EDC2 (CD147), EDC3 (CD98), EDC5 (CD44), and EDC8 (CD38). Its product EDC1 combines two proteins found in close proximity to treat …
  • Sumitomo Dainippon Pharma Co Ltd (4506):製薬・医療:M&Aディール及び事業提携情報
    Summary Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co., Ltd, develops manufacturers, purchases, sells, imports and exports pharmaceutical products. The company focuses on major therapeutic areas which include central nervous system (CNS), cardiovascular, …
  • International SOS Pte Ltd:企業の戦略的SWOT分析
    International SOS Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Bio-Path Holdings Inc (BPTH):企業の財務・戦略的SWOT分析
    Summary Bio-Path Holdings Inc (Bio-Path) is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen (Liposomal Grb2 Antisense) …
  • Duvel Moortgat NV:企業の戦略的SWOT分析
    Duvel Moortgat NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Patel Engineering Ltd:企業の戦略・SWOT・財務情報
    Patel Engineering Ltd - Strategy, SWOT and Corporate Finance Report Summary Patel Engineering Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • KDDI Corporation (9433):企業の財務・戦略的SWOT分析
    KDDI Corporation (9433) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Voyager Therapeutics Inc (VYGR):製薬・医療:M&Aディール及び事業提携情報
    Summary Voyager Therapeutics Inc (Voyager) is a clinical-stage gene therapy company that develops treatments for patients suffering from severe neurological diseases. The company provides treatment for adeno-associated virus gene therapy field by selecting, designing and manufacturing vectors. Its c …
  • MAN SE:企業の戦略・SWOT・財務分析
    MAN SE - Strategy, SWOT and Corporate Finance Report Summary MAN SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • PSR Group BV:製薬・医療:M&Aディール及び事業提携情報
    Summary PSR Group BV (PSR) is a contract research and staffing consultancy service provider. The company operates through two divisions such as PSR Orphan Experts and PSR Pharma Resource. Its PSR Orphan Experts is a contract research organization that concentrates on orphan drug development. The com …
  • China Mobile Ltd (941):企業の財務・戦略的SWOT分析
    China Mobile Ltd (941) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆